文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

耐多药结核治疗中利奈唑胺相关周围神经病变的三种管理策略比较:目标试验模拟

Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation.
PubMed 文献 · Clin Infect Dis · 2026-06-12

该目标试验模拟基于endTB观察性研究,纳入12国303例在MDR/RR-TB治疗6个月内出现非严重周围神经病变且每日服利奈唑胺600mg者,比较立即调整、延迟调整与不调整三种策略。结果显示立即调整与不调整的治疗成功率相似(84.7% vs 85.2%),无实质负面影响证据。

要点

  • 非严重周围神经病变出现后立即调整利奈唑胺未显著降低治疗成功率。
  • 立即调整与不调整的成功率比为0.99(95%CI 0.83–1.11)。
  • 结果支持临床按需谨慎调整利奈唑胺以管理非严重周围神经病变。

核心结论

  • 未发现立即调整利奈唑胺对MDR/RR-TB治疗成功产生实质性负面影响的证据。
  • 结果支持在需要时谨慎调整利奈唑胺以管理非严重周围神经病变的临床实践。

研究设计与样本

  • 采用目标试验模拟方法,数据来自endTB观察性研究。
  • 纳入12个国家303例在开始个体化MDR/RR-TB方案6个月内每日服利奈唑胺600mg并出现非严重周围神经病变者。
  • 比较周围神经病变发生后第1–7周内立即调整、第8–26周延迟调整、第1–26周不调整三种策略。
  • 采用克隆-删失及逆概率删失加权以模拟符合方案分析。

主要发现

  • 周围神经病变发生于治疗开始后中位11周(四分位距4–18周)。
  • 加权标准化治疗成功概率:立即调整84.7%(95%CI 69.2%–92.9%),延迟调整78.9%(95%CI 65.9%–87.1%),不调整85.2%(95%CI 80.5%–89.1%)。
  • 与不调整相比,治疗成功比:立即调整0.99(95%CI 0.83–1.11),延迟调整0.93(95%CI 0.78–1.01)。

关键数值与推荐

  • 利奈唑胺剂量为每日600mg。
  • 非严重周围神经病变出现后立即调整定义为第1–7周内剂量降低、暂时中断或停药。
  • 延迟调整定义为第8–26周内调整;不调整定义为第1–26周继续每日600mg。

临床怎么用

  • 对MDR/RR-TB治疗中出现非严重周围神经病变者,可考虑在需要时立即谨慎调整利奈唑胺而无需过度担忧治疗成功受损。
  • 调整方式包括剂量降低、暂时中断或停药,具体应结合临床判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. METHODS: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1-7 after peripheral neuropathy onset, deferred change within Weeks 8-26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1-26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. RESULTS: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4-18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. CONCLUSIONS: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Romo M, LaHood A, Mitnick CD, et al. Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation. Clin Infect Dis. 2026. PMID: 42283325. doi:10.1093/cid/ciag361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。